Skip Nav Destination
Bortezomib with chemotherapy is highly active in advanced B-precursor acute lymphoblastic leukemia: Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Study
Allogeneic hematopoietic stem cell transplantation in thalassemia major: results of a reduced-toxicity conditioning regimen based on the use of treosulfan
Issue Archive
July 12 2012
In this Issue
Table of Contents
Inside Blood
Blood Work
Plenary Paper
MYELOID NEOPLASIA
miR-3151 interplays with its host gene BAALC and independently affects outcome of patients with cytogenetically normal acute myeloid leukemia
Ann-Kathrin Eisfeld,Guido Marcucci,Kati Maharry,Sebastian Schwind,Michael D. Radmacher,Deedra Nicolet,Heiko Becker,Krzysztof Mrózek,Susan P. Whitman,Klaus H. Metzeler,Jason H. Mendler,Yue-Zhong Wu,Sandya Liyanarachchi,Ravi Patel,Maria R. Baer,Bayard L. Powell,Thomas H. Carter,Joseph O. Moore,Jonathan E. Kolitz,Meir Wetzler,Michael A. Caligiuri,Richard A. Larson,Stephan M. Tanner,Albert de la Chapelle,Clara D. Bloomfield
Perspectives
Review Article
How I Treat
Clinical Trials and Observations
Bortezomib with chemotherapy is highly active in advanced B-precursor acute lymphoblastic leukemia: Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Study
Clinical Trials & Observations
Yoav H. Messinger,Paul S. Gaynon,Richard Sposto,Jeannette van der Giessen,Elena Eckroth,Jemily Malvar,Bruce C. Bostrom,for the Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Consortium
Hematopoiesis and Stem Cells
Lymphoid Neoplasia
Myeloid Neoplasia
GATA2 zinc finger 1 mutations associated with biallelic CEBPA mutations define a unique genetic entity of acute myeloid leukemia
Philipp A. Greif,Annika Dufour,Nikola P. Konstandin,Bianka Ksienzyk,Evelyn Zellmeier,Belay Tizazu,Jutta Sturm,Tobias Benthaus,Tobias Herold,Marjan Yaghmaie,Petra Dörge,Karl-Peter Hopfner,Andreas Hauser,Alexander Graf,Stefan Krebs,Helmut Blum,Purvi M. Kakadia,Stephanie Schneider,Eva Hoster,Friederike Schneider,Martin Stanulla,Jan Braess,Maria Cristina Sauerland,Wolfgang E. Berdel,Thomas Büchner,Bernhard J. Woermann,Wolfgang Hiddemann,Karsten Spiekermann,Stefan K. Bohlander
Platelets and Thrombopoiesis
SLC35D3 delivery from megakaryocyte early endosomes is required for platelet dense granule biogenesis and is differentially defective in Hermansky-Pudlak syndrome models
Ronghua Meng,Yuhuan Wang,Yu Yao,Zhe Zhang,Dawn C. Harper,Harry F. G. Heijnen,Anand Sitaram,Wei Li,Graça Raposo,Mitchell J. Weiss,Mortimer Poncz,Michael S. Marks
Red Cells, Iron, and Erythropoiesis
Thrombosis and Hemostasis
Residual plasmatic activity of ADAMTS13 is correlated with phenotype severity in congenital thrombotic thrombocytopenic purpura
Luca A. Lotta,Haifeng M. Wu,Ian J. Mackie,Marina Noris,Agnes Veyradier,Marie A. Scully,Giuseppe Remuzzi,Paul Coppo,Ri Liesner,Roberta Donadelli,Chantal Loirat,Richard A. Gibbs,April Horne,Shangbin Yang,Isabella Garagiola,Khaled M. Musallam,Flora Peyvandi
Transplantation
Detectable minimal residual disease before hematopoietic cell transplantation is prognostic but does not preclude cure for children with very-high-risk leukemia
Wing Leung,Ching-Hon Pui,Elaine Coustan-Smith,Jie Yang,Deqing Pei,Kwan Gan,Ashok Srinivasan,Christine Hartford,Brandon M. Triplett,Mari Dallas,Asha Pillai,David Shook,Jeffrey E. Rubnitz,John T. Sandlund,Sima Jeha,Hiroto Inaba,Raul C. Ribeiro,Rupert Handgretinger,Joseph H. Laver,Dario Campana
Allogeneic hematopoietic stem cell transplantation in thalassemia major: results of a reduced-toxicity conditioning regimen based on the use of treosulfan
Brief Report
Maria Ester Bernardo,Eugenia Piras,Adriana Vacca,Giovanna Giorgiani,Marco Zecca,Alice Bertaina,Daria Pagliara,Benedetta Contoli,Rita Maria Pinto,Giovanni Caocci,Angela Mastronuzzi,Giorgio La Nasa,Franco Locatelli
Vascular Biology
GFI1 and GFI1B control the loss of endothelial identity of hemogenic endothelium during hematopoietic commitment
Christophe Lancrin,Milena Mazan,Monika Stefanska,Rahima Patel,Monika Lichtinger,Guilherme Costa,Özge Vargel,Nicola K. Wilson,Tarik Möröy,Constanze Bonifer,Berthold Göttgens,Valerie Kouskoff,Georges Lacaud
CDP-diacylglycerol synthetase-controlled phosphoinositide availability limits VEGFA signaling and vascular morphogenesis
Weijun Pan,Van N. Pham,Amber N. Stratman,Daniel Castranova,Makoto Kamei,Kameha R. Kidd,Brigid D. Lo,Kenna M. Shaw,Jesus Torres-Vazquez,Constantinos M. Mikelis,J. Silvio Gutkind,George E. Davis,Brant M. Weinstein
-
Cover Image
Cover Image
![issue cover]()
PTH treatment alters the bone marrow microarchitecture. A representative image of hematoxylin and eosin–stained paraffin section from the distal femur of a PTH-treated mouse. The increased trabecular structures (in pink) are surrounded by the hematopoietic marrow cells (in blue). See the article by Bromberg et al on page 303.
- PDF Icon PDF LinkFront Matter
- PDF Icon PDF LinkTable of Contents
- PDF Icon PDF LinkBack Matter
- PDF Icon PDF LinkAdvertising
- PDF Icon PDF LinkEditorial Board
Advertisement
Email alerts
Advertisement
